On April 2, 2021, viloxazine, brand name Qelbree, received FDA approval for the treatment of ADHD in children and adolescents ages 6-17 years old. The latest issue of The Carlat Child Psychiatry Report includes a News of Note covering this newly approved medication for ADHD. In this podcast, we discuss the advantages and disadvantages of viloxazine for children and adolescents with ADHD.
Published On: 6/21/2021
Duration: 11 minutes, 55 seconds
Related Article: "Viloxazine (Qelbree): A Faster Strattera? (https://www.thecarlatreport.com/the-carlat-child-psychiatry-report/viloxazine-qelbree-a-faster-strattera/)", The Carlat Child Psychiatry Report, April/May/June 2021
Resources:

* Nasser A et al, Clin Ther 2020;42(8):1452–1466
* Johnson JK et al, J Atten Disord 2020;24(2):348-358
* Faraone SV, P T. 2009;34(12):678-683, 694.
* de Silva V et al, BMC Psychiatry 2011;11:176.

Got Feedback? Take the podcast survey (http://www.thecarlatreport.com/podcastsurvey).

Viloxazine (Qelbree): A Faster Strattera?

Clear, engaging, and practical updates on clinical psychiatry. Hosted by Chris Aiken, MD, and Kellie Newsome, PMHNP.    
Earn CME for listening at www.thecarlatreport.com/podcastcme

Alternative Health

Health

Medicine

Science & Medicine

Health & Fitness

Mental Health

What steps should clinicians take if psychopharmacologic treatments and school behavioral strategies are insufficient for managing a child with ADHD? We've all been there. ADHD, attention deficit hyperactivity disorder, of course, affects millions of children and adolescents worldwide and can significantly impact focus, impulses, and engagement with friends.Parents and caregivers need to understand the different kinds of medications and therapies that are available to help manage ADHD. In this podcast, Mara and I will explore the various treatment options for ADHD in children and discuss how to navigate the process of selecting more effective treatments.﻿Published On: 04/22/2024Duration: 26 minutes, 43  secondsJoshua Feder, MD, and Mara Goverman, LCSW, have disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

ADHD Algorithm

In today's episode, Dr. Brian Hurley provides expert insights into the current state of stimulant use disorder, its implications across different regions, and available treatment options. CME: Take the CME Post-Test for this EpisodePublished On: 04/15/2024Duration: 30 minutes, 43 secondNoah Capurso, MD, Brian Hurley, MD have disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Stimulant Update with Dr. Brian Hurley

Does psychiatry keep making the same mistakes? Edward Shorter gives us a historical perspective. CME: Take the CME Post-Test for this EpisodePublished On: 04/08/2024Duration: 22 minutes, 16 secondChris Aiken, MD, Edward Shorter, PhD and Kellie Newsome, PMHNP have disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Controversies in Psychiatry

Viibryd has gone generic, but is it worth prescribing? We review all there is to know about vilazodone in this update from our #1 most read article of 2023.CME: Take the CME Post-Test for this EpisodePublished On: 04/01/2024Duration: 12 minutes, 47 secondChris Aiken, MD, and Kellie Newsome, PMHNP have disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Viibryd Goes Generic

All sorts of medications are prescribed for anxiety in older adults. Today, we look at when and how to discontinue them.CME: Take the CME Post-Test for this EpisodePublished On: 03/25/2024Duration: 22 minutes, 47 secondChris Aiken, MD, and Kellie Newsome, PMHNP have disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Viloxazine (Qelbree): A Faster Strattera?

Download our free app to listen on your phone